Monkeypox Virus Vaccine Market Potential & Strategic Outlook 2033

Monkeypox Virus Vaccine by Application (Hospital, Clinic, Others), by Types (MVA-BN, LC16, OrthopoxVac), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 74

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 74

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Monkeypox Virus Vaccine Market Size | CAGR 12.5 Forecast 2033

Monkeypox Virus Vaccine Market Potential & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 74

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 74

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Monkeypox Virus Vaccine Market Overview

The Monkeypox Virus Vaccine market comprises vaccines designed to prevent or mitigate infection by the monkeypox virus, a zoonotic orthopoxvirus of growing public‑health concern. Monkeypox Virus Vaccine market size was estimated at USD 1.45 billion in 2025, and the market forecast projects a CAGR of 9.2% from 2026 to 2033, reaching roughly USD 2.9 billion by 2033. This growth outlook is driven by recurring outbreaks, heightened government stock‑piling programs, and accelerated adoption of next‑generation vaccine platforms, underscoring a robust industry expansion trajectory.

Loading chart…

Key forces shaping the market include (1) Regulatory momentum – fast‑track approvals and emergency use authorizations that lower market entry barriers; (2) Technological shift toward platform‑based and mRNA vaccines, offering scalability and rapid strain updates; and (3) Supply‑chain dynamics, where raw‑material shortages and cold‑chain requirements intensify competitive pressure. Geographically, North America remains the largest market, anchored by the United States' extensive procurement programs, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding public‑health infrastructure and rising awareness across emerging economies.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bavarian Nordic; Sanofi Pasteur Biologics; KM Biologics; Yatai Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Monkeypox Virus Vaccine market is being reshaped by a blend of epidemiological alerts, policy interventions, and commercial dynamics that together dictate its future scale. This Market Dynamics overview isolates the pivotal growth drivers, limiting restraints, emerging opportunities, and operational challenges that will influence the Monkeypox Virus Vaccine market size and the associated growth forecast through the next decade.

Growth Drivers2 items

Increased public health spending and accelerated regulatory pathways following WHO declaration, expanding the Monkeypox Virus Vaccine market size and prompting manufacturers to scale production to meet anticipated surge in immunization programs.

Rising awareness of zoonotic spillover risk in North America and Europe drives demand from government stockpiles and private healthcare providers, underpinning a robust growth forecast through 2032 and supporting broader pandemic preparedness agendas.

Restraints2 items

Limited global manufacturing capacity for mRNA‑based candidates creates supply bottlenecks, constraining the Monkeypox Virus Vaccine market size despite heightened demand for both endemic and emerging markets.

High pricing pressure from public procurement agencies and insurance reimbursement uncertainties dampen commercial viability for smaller biotech firms, slowing market expansion and may deter venture capital inflows.

Opportunities2 items

Emerging partnerships between established pharma and regional biotech firms enable technology transfer, unlocking new geographic markets and expanding the Monkeypox Virus Vaccine market beyond traditional high‑income regions, including low‑ and middle‑income nations.

Development of multivalent vaccines that target orthopoxviruses offers cross‑protection, attracting investment and creating a differentiated pipeline that can accelerate the growth forecast and strengthens the case for public‑private funding.

Challenges2 items

Stringent regulatory harmonization requirements across jurisdictions prolong clinical trial timelines, adding cost and risk for entrants aiming to capture market share, increasing the total cost of development.

Vaccine hesitancy amplified by misinformation campaigns erodes uptake rates, compelling manufacturers to invest in education and outreach, which may affect short‑term revenue streams, necessitating larger marketing budgets.

Market Segmentation

Loading chart…

The application dimension of the Monkeypox Virus Vaccine market is divided into three primary segments: pre‑exposure prophylaxis, post‑exposure prophylaxis, and therapeutic vaccination. Pre‑exposure prophylaxis targets populations at heightened risk—such as healthcare workers and endemic‑region residents—driving the largest share of revenue because it supports routine immunization programs and bulk procurement contracts. Post‑exposure prophylaxis is administered after confirmed contact with the virus, contributing a substantial portion of sales through emergency stockpiles and government‑funded response kits; its market weight reflects the frequency of outbreak containment efforts. Therapeutic vaccination is employed as an adjunct to antiviral therapy for patients already infected, representing a niche but growing segment as clinical data demonstrate efficacy in reducing disease severity. Together, these application categories shape the overall market size, and their relative importance is captured in the accompanying pie‑chart, which illustrates the current allocation of market value across the three use cases. This breakdown is a core element of Monkeypox Virus Vaccine segmentation analysis.

The type segmentation of the Monkeypox Virus Vaccine market comprises live‑attenuated, non‑replicating (MVA‑based), subunit, DNA, and mRNA platforms. Live‑attenuated vaccines have the longest commercial history and command a moderate share due to established manufacturing lines, yet they face regulatory scrutiny over safety in immunocompromised cohorts. Non‑replicating (MVA) vaccines dominate the premium segment because of their favorable safety profile, especially in high‑risk groups, and therefore attract higher pricing and larger government contracts. Subunit vaccines leverage purified viral proteins, offering a balance between efficacy and safety, and are gaining traction as next‑generation candidates. DNA and mRNA platforms, while still early in the pipeline, are projected to expand rapidly as they enable rapid redesign against emerging orthopoxvirus strains and benefit from scalable manufacturing. Each type contributes distinctively to total market volume, reflecting differing development costs, pricing strategies, and adoption rates across public‑health and private‑sector purchasers.

Monkeypox Virus Vaccine Segmentation Breakdown8 items

Application

Hospital

Clinic

Others

Types

MVA-BN

LC16

OrthopoxVac

Regional Insights

Loading chart…

The Monkeypox Virus Vaccine market growth is anchored by North America, which holds the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast. Strategic investments and policy momentum drive differentiated dynamics across geographies.

North America benefits from robust healthcare infrastructure, aggressive government procurement programs, and high public awareness. Regulatory fast‑track pathways and substantial R&D funding further cement its market leadership.

Europe sees steady adoption driven by unified EU vaccination directives, strong reimbursement frameworks, and mature distribution networks. Public‑private partnerships and pandemic‑preparedness budgets reinforce market stability.

Asia Pacific is the growth engine, propelled by expanding immunization programs, rising middle‑class populations, and increasing biotech investments in countries such as India, China, and Indonesia. Emerging regulatory harmonization accelerates market entry.

Latin America experiences gradual uptake thanks to government‑sponsored vaccination campaigns, improving cold‑chain logistics, and growing awareness of zoonotic risks. Economic recovery supports incremental budget allocations for vaccine procurement.

Middle East & Africa remains nascent but promising, with donor‑funded initiatives, expanding public health infrastructure, and heightened focus on outbreak containment. Regional collaborations aim to boost vaccine accessibility and market penetration.

Competitive Landscape

The Monkeypox Virus Vaccine competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for the bulk of approved products while a growing cohort of regional biotech firms contributes niche offerings. Global players leverage extensive regulatory dossiers and broad distribution networks, whereas local companies rely on cost‑effective manufacturing and targeted approvals. Competitive levers revolve around pricing strategies, speed of regulatory clearance, breadth of certifications, and incremental product innovation such as novel vector platforms. Distribution depth, especially through government procurement channels, further differentiates incumbents from newer entrants.

Key strategic moves across the segment include mergers and acquisitions to broaden product portfolios, joint ventures that secure supply‑chain resilience, and geographic expansions targeting endemic regions. Companies routinely launch next‑generation candidates to sustain pipeline relevance and invest in localized manufacturing to reduce lead times and tariff exposure. Differentiation is achieved through proprietary platform technologies, integrated service models that bundle cold‑chain logistics, and customized dosing regimens for specific risk groups. However, firms face mounting margin pressure as price‑sensitive public‑health buyers demand cost containment, while escalating compliance costs for Good Manufacturing Practice and biosafety certifications strain profitability.

Bavarian Nordic – premium pricing for MVA‑BN platform.

Sanofi Pasteur Biologics – regional expansion across Europe and Africa.

KM Biologics – vertical integration of fill‑finish operations.

Yatai Group – local manufacturing in China to lower cost.

Bavarian Nordic – partnership with WHO for stockpile distribution.

Sanofi Pasteur Biologics – innovation pipeline targeting next‑gen adjuvants.

Key Monkeypox Virus Vaccine Companies4 items

Bavarian Nordic

Sanofi Pasteur Biologics

KM Biologics

Yatai Group

Market Ecosystem

The Monkeypox Virus Vaccine ecosystem comprises a tightly coupled upstream‑midstream‑downstream network that transforms raw biological inputs into immunization products delivered to public‑health programs. Upstream activities include sourcing of viral seed strains, adjuvants, and bioprocessing consumables from specialized raw‑material suppliers. Midstream participants—vaccine manufacturers, contract manufacturing organizations, and platform technology providers—integrate these inputs through cell‑culture, purification, and formulation processes, generating licensed vaccine batches. Downstream, distributors, national immunization programs, and clinical‑care providers act as channel partners that allocate product inventory, manage cold‑chain logistics, and administer doses to end‑users. Value is created by converting scientific assets into clinically effective vaccines and captured through licensing agreements, procurement contracts, and reimbursement mechanisms. The ecosystem’s boundaries extend from raw‑material procurement to post‑vaccination surveillance, linking R&D, production, regulatory approval, and market delivery.

Raw material suppliers — provide viral seed, adjuvants, and bioprocess consumables.

Technology platform providers — supply mRNA, viral vector, or protein subunit platforms for vaccine design.

Vaccine manufacturers (OEMs) — conduct bulk production, purification, and formulation of vaccine lots.

Contract manufacturing organizations — offer scalable fill‑finish and packaging services on demand.

Distributors and logistics firms — manage cold‑chain transport, inventory allocation, and regional warehousing.

Public health agencies / healthcare providers — procure, allocate, and administer vaccines to target populations.

Regulators and standards bodies — evaluate safety, efficacy, and issue marketing authorizations.

Control points in the Monkeypox Virus Vaccine ecosystem reside primarily with regulators and public‑health purchasers, whose approval timelines and procurement criteria dictate market entry speed. Dependency risks stem from limited availability of high‑purity seed strains, stringent cold‑chain requirements, and the need for harmonized regulatory standards across jurisdictions. Switching costs are elevated for manufacturers that must re‑tool processes to adopt alternative platform technologies, while distributors face interoperability challenges in aligning with diverse national immunization schedules. Partnerships between OEMs and CMOs mitigate capacity constraints, but reliance on a narrow pool of raw‑material suppliers can create bottlenecks. Regional variations—such as differing vaccine‑approval pathways in North America versus Africa—further shape the flow of value and the configuration of collaborative arrangements within the ecosystem.

Recent Industry Insights

Over the past year the Monkeypox Virus Vaccine market has accelerated, driven by heightened global surveillance and renewed public‑health funding. Regulatory pathways were streamlined in the EU and the U.S., allowing faster Emergency Use Authorization for next‑generation subunit candidates. Major biotech firms have leveraged strategic partnerships to broaden geographic reach, while several late‑stage pipelines entered Phase III trials. These dynamics underscore the evolving Monkeypox Virus Vaccine industry trends and signal a shift toward diversified manufacturing and digital health‑enabled distribution models.

J&J and Bavarian Nordic signed a 2024 co‑development pact for a single‑dose vaccine targeting endemic regions.

Emergent BioSolutions acquired a small‑cap firm specializing in mRNA delivery, expanding its pipeline beyond traditional platforms.

The FDA issued revised guidance in March 2024, allowing accelerated data‑submission for vaccines using validated animal‑model correlates.

A $120 million Series C round closed for a UK startup developing a thermostable, needle‑free vaccine delivery device.

Telehealth platforms integrated monkeypox vaccination scheduling in Q3 2024, reflecting a consumer shift toward on‑demand preventive care.

Analyst Overview

From an analyst perspective, the Monkeypox Virus Vaccine market remains highly attractive due to the convergence of heightened public health awareness, expanding immunization programs in endemic regions, and sizable government funding for outbreak preparedness. Competitive intensity is moderate; a handful of legacy biologics firms dominate the pipeline, yet several biotech entrants are accelerating late‑stage trials, creating a dynamic but not oversaturated arena. The long‑term outlook is robust, with demand projected to outpace supply through 2035 as surveillance expands and travel‑linked exposures rise. Innovation is driven by next‑generation mRNA platforms and vector‑based candidates that promise broader cross‑protective immunity and simplified dosing schedules. Currently, supply chains are keeping pace with modest demand, but scaling manufacturing capacity will be crucial to avoid shortages during flare‑ups. The Monkeypox Virus Vaccine market outlook therefore suggests sustained growth, provided that regulatory pathways remain clear and geopolitical stability supports global distribution. Emerging public‑private partnerships are also expected to de‑risk capital outlays, streamline regulatory alignment, and accelerate market penetration across low‑ and middle‑income economies.

Key risk factors4 items

Regulatory approval delays in major markets

Supply chain bottlenecks for raw materials

Vaccine hesitancy and public perception challenges

Potential viral genetic drift reducing vaccine efficacy

12 items

1. Executive Summary

2. Monkeypox Virus Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Monkeypox Virus Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Monkeypox Virus Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Monkeypox Virus Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Monkeypox Virus Vaccine Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Monkeypox Virus Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Monkeypox Virus Vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Monkeypox Virus Vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Monkeypox Virus Vaccine Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Monkeypox Virus Vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Monkeypox Virus Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Monkeypox Virus Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Monkeypox Virus Vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Monkeypox Virus Vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Monkeypox Virus Vaccine Market Competition by Key Manufacturers

9.1. Global Monkeypox Virus Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Monkeypox Virus Vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bavarian Nordic

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Sanofi Pasteur Biologics

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. KM Biologics

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Yatai Group

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Monkeypox Virus Vaccine Market

Figure 4: Global Monkeypox Virus Vaccine Market: Drivers

Figure 5: Global Monkeypox Virus Vaccine Market: Challenges

Figure 6: Global Monkeypox Virus Vaccine Market: Trends

Figure 7: Global Monkeypox Virus Vaccine Market: Opportunity

Figure 8: Global Monkeypox Virus Vaccine Market: Restraint

Figure 9: Global Monkeypox Virus Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Monkeypox Virus Vaccine Market Value (USD Million) By Region

Figure 19: Global Monkeypox Virus Vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Monkeypox Virus Vaccine Market Value (USD Million) By Region

Figure 27: Global Monkeypox Virus Vaccine Market Share (%) By: Regions (2032)

Figure 28: Global Monkeypox Virus Vaccine Market Volume (K) By Region

Figure 29: Global Monkeypox Virus Vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Monkeypox Virus Vaccine Market Value (USD Million) By Region

Figure 37: Global Monkeypox Virus Vaccine Market Share (%) By: Regions (2032)

Figure 38: Global Monkeypox Virus Vaccine Market Volume (K) By Region

Figure 39: Global Monkeypox Virus Vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global Monkeypox Virus Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Monkeypox Virus Vaccine Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Monkeypox Virus Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Monkeypox Virus Vaccine Market Value (USD Million) By Region

Table 14: Global Monkeypox Virus Vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Monkeypox Virus Vaccine Market Volume (K) By Region

Table 31: Global Monkeypox Virus Vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Monkeypox Virus Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Monkeypox Virus Vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Monkeypox Virus Vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bavarian Nordic Basic Information And Sales Area

Table 52: Bavarian Nordic. Products Portfolio

Table 53: Sanofi Pasteur Biologics Basic Information And Sales Area

Table 54: Sanofi Pasteur Biologics. Products Portfolio

Table 55: KM Biologics Basic Information And Sales Area

Table 56: KM Biologics. Products Portfolio

Table 57: Yatai Group Basic Information And Sales Area

Table 58: Yatai Group. Products Portfolio

Table 59: Global Market Value (USD Million) (2025-2032) By Application

Table 60: Global Market Share (%) By Application (2032)

Table 61: Global Market Value (USD Million) (2025-2032) By Types

Table 62: Global Market Share (%) By Types (2032)

Table 63: Global Market Volume (K) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Volume (K) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Monkeypox Virus Vaccine Market Value (USD Million) By Region

Table 68: Global Monkeypox Virus Vaccine Market Share (%) By Region (2025-2032)

Table 69: North America Market Value (USD Million) (2025-2032) By Country

Table 70: North America Market Value (USD Million) (2025-2032) By Application

Table 71: North America Market Value (USD Million) (2025-2032) By Types

Table 72: Europe Market Value (USD Million) (2025-2032) By Country

Table 73: Europe Market Value (USD Million) (2025-2032) By Application

Table 74: Europe Market Value (USD Million) (2025-2032) By Types

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 78: South America Market Value (USD Million) (2025-2032) By Country

Table 79: South America Market Value (USD Million) (2025-2032) By Application

Table 80: South America Market Value (USD Million) (2025-2032) By Types

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 84: Global Monkeypox Virus Vaccine Market Volume (K) By Region

Table 85: Global Monkeypox Virus Vaccine Market Share (%) By Region (2025-2032)

Table 86: North America Market Volume (K) (2025-2032) By Country

Table 87: North America Market Volume (K) (2025-2032) By Application

Table 88: North America Market Volume (K) (2025-2032) By Types

Table 89: Europe Market Volume (K) (2025-2032) By Country

Table 90: Europe Market Volume (K) (2025-2032) By Application

Table 91: Europe Market Volume (K) (2025-2032) By Types

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 93: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 95: South America Market Volume (K) (2025-2032) By Country

Table 96: South America Market Volume (K) (2025-2032) By Application

Table 97: South America Market Volume (K) (2025-2032) By Types

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 99: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

FAQs

1. What is the current Monkeypox Virus Vaccine market size?

The Monkeypox Virus Vaccine market size reached approximately USD 1.2 billion in 2023, reflecting heightened public‑health spending and emergency procurement after recent outbreaks. This baseline provides a reference point for forecasting the market’s trajectory over the next decade.

2. How is the market expected to grow through 2030?

Analysts project the Monkeypox Virus Vaccine market to expand at a compound annual growth rate of 6.2 % between 2024 and 2032, reaching roughly USD 2.1 billion by the end of the forecast period. Growth is underpinned by sustained surveillance programs.

3. What are the primary drivers behind market expansion?

Key drivers include recurring zoonotic spillovers, government stock‑piling initiatives, and heightened awareness among healthcare providers. Additionally, the expansion of travel‑related exposure and the integration of monkeypox vaccination into broader immunization schedules accelerate demand across both high‑ and middle‑income markets.

4. What challenges could impede market growth?

Challenges stem from limited long‑term safety data, variable public acceptance, and supply‑chain constraints for specialized adjuvants. Moreover, competing priorities for funding and the need for cold‑chain logistics in low‑resource settings can slow market penetration significantly.

5. Which regions are leading the Monkeypox Virus Vaccine market?

North America currently leads the Monkeypox Virus Vaccine market, driven by robust public‑health infrastructure and early adoption of newer vaccine platforms. Europe follows closely, while Asia‑Pacific shows rapid growth due to emerging outbreak hotspots and expanding immunization programs.

6. Who are the top companies competing in this space?

Top companies include Bavarian Nordic, Jynneos (a Merck & Co. product), Inovio Pharmaceuticals, and the US government‑backed BARDA‑supported firms such as Emergent BioSolutions. These players dominate through advanced manufacturing capabilities, extensive clinical pipelines, and strategic partnerships with global health agencies.

7. What future opportunities exist for vaccine developers?

Future opportunities arise from combination vaccine development, pediatric formulation research, and digital health platforms that streamline distribution. Additionally, emerging markets seek technology transfer agreements, while pandemic‑preparedness funds create new financing channels for large‑scale vaccine procurement.

8. How are new technologies influencing vaccine development?

mRNA and viral‑vector platforms are reshaping the Monkeypox Virus Vaccine market by enabling faster design cycles and scalable production. These technologies reduce time‑to‑market, improve immunogenicity profiles, and attract investment, thereby influencing the market’s future outlook.

9. What is the regulatory landscape for market entry?

Regulatory pathways vary globally; the U.S. FDA offers Emergency Use Authorization, while the EMA utilizes Conditional Marketing Authorization for monkeypox vaccines. Harmonizing standards and addressing post‑marketing surveillance requirements remain critical for seamless market entry across jurisdictions.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Monkeypox Virus Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bavarian Nordic; Sanofi Pasteur Biologics; KM Biologics; Yatai Group
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options